Prostate Cancer - Localized Adenocarcinoma Proton Therapy

A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With a Localized Prostate Adenocarcinoma

A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma

For Proton therapy with prostate adenocarcinoma patients.

Arm 1: Proton therapy 3CGE x 20days = Total 60 CGE for 4 weeks.

Arm 2: Proton therapy 4.7CGE x 10days = Total 47 CGE for 2 weeks.

Inclusion Criteria:

• Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0
• ECOG performance status:0-1
• Signed study specific informed consent prior to study entry.

Exclusion Criteria:

• Postoperative residual or recurrent tumor
• Evidence of distant metastasis previous irradiation for the tumor in the same location
• Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)